GlassScriptPhysician profile
Stephanie Mcwhirter
NPI 1376085365
$8,579.65
in general payments reported to CMS, 2019-2025
27 companies · $2,408 in 2025
The $2,408 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $1,278 · 2023: $1,872 · 2024: $2,495 · 2025: $2,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.93 |
| Education | $283.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,230.93 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $1,167.02 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $761.81 | 2021-2025 | |
| Ucb, INC. | $745.16 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $702.77 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $673.00 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $638.03 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $517.81 | 2021-2025 | |
| Dermavant Sciences, INC. | $401.24 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $311.83 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $216.70 | 2023-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $184.99 | 2022-2025 | |
| Smith+Nephew, INC. | $162.86 | 2024-2025 | Grafix Pl, Stravix Pl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.27 | 2023-2025 | Cyltezo, Spevigo |
| Organon LLC | $110.87 | 2024-2025 | Hadlima, Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $104.11 | 2021-2024 | |
| Leo Pharma INC. | $90.53 | 2021-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $74.13 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $67.33 | 2025 | Otezla |
| Janssen Scientific Affairs, LLC | $52.31 | 2021 | |
| Incyte Corporation | $46.26 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $40.54 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $35.16 | 2024-2025 | Zoryve |
| Solta Medical, A Division of Bausch Health US, LLC | $31.01 | 2025 | |
| Surgenex LLC | $25.99 | 2025 | Renograft, Surmatrix, Pellograft |
| Genentech USA, INC. | $22.67 | 2025 | Xolair |
| Blueprint Medicines Corporation | $20.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Mcwhirter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.